Study Finds That Surgery May be Best for Cushing’s Disease Patients With Unclear MRI Findings
sasint / Pixabay

Study Finds That Surgery May be Best for Cushing’s Disease Patients With Unclear MRI Findings

According to a story from the CushieBlog, a recent study has found that a certain surgical procedure may be the best course of treatment for patients with Cushing's disease whose…

Continue Reading Study Finds That Surgery May be Best for Cushing’s Disease Patients With Unclear MRI Findings
Congressmen Introduce Bill to Help Chronic Inflammatory Demyelinating Polyneuropathy Patients and Others
skeeze / Pixabay

Congressmen Introduce Bill to Help Chronic Inflammatory Demyelinating Polyneuropathy Patients and Others

According to a story from the website of Oregon rep Earl Blumenauer, Blumenauer (D-OR) along with fellow congressmen George Holding (R-NC) and G. K. Butterfield (D-NC) have introduced a bill…

Continue Reading Congressmen Introduce Bill to Help Chronic Inflammatory Demyelinating Polyneuropathy Patients and Others

Program Established by the NIH to Help Rare Disease Advocacy Groups Start Patient Registries

The Beginnings Anne Pariser worked for 16 years at the FDA. For part of that time, she was a team leader for the Center for Drug Evaluation and Research where…

Continue Reading Program Established by the NIH to Help Rare Disease Advocacy Groups Start Patient Registries

Experimental Drug for Sickle Cell Disease Earns Fast Track Designation

According to a story from BioSpace, the biopharmaceutical company Imara, Inc. has recently announced that its experimental product candidate IMR-687 has earned Fast Track designation from the US Food and…

Continue Reading Experimental Drug for Sickle Cell Disease Earns Fast Track Designation

Transthyretin-Mediated Amyloidosis (ATTR-CM); After Nine Years Pfizer Wins FDA Breakthrough Designation

It has been nine years since Pfizer acquired the drugs vyndagel and vyndamax. According to a report in Biospace, based on the FDA’s recent approval of the two drugs to treat transthyretin-mediated…

Continue Reading Transthyretin-Mediated Amyloidosis (ATTR-CM); After Nine Years Pfizer Wins FDA Breakthrough Designation
Experimental Treatment for Spinocerebellar Ataxia Earns Orphan Drug Designation
jarmoluk / Pixabay

Experimental Treatment for Spinocerebellar Ataxia Earns Orphan Drug Designation

According to a story from BioSpace, the drug developer Cadent Therapeutics recently announced that its investigational product candidate CAD-1883 has earned Orphan Drug Designation from the US Food and Drug…

Continue Reading Experimental Treatment for Spinocerebellar Ataxia Earns Orphan Drug Designation
Close Menu